MedicineEurope PMC
Heuristic editor, no API keyVerdict: MajorAge and antiplatelet de-escalation after myocardial infarction in the TALOS-AMI trial
Background The clinical effects of dual antiplatelet therapy de-escalation after acute myocardial infarction may differ by age.
Key numbers
- 16.8% women
- 4.1% vs
- 95% CI
VerdictA leading story on any desk.
Abstract
Background The clinical effects of dual antiplatelet therapy de-escalation after acute myocardial infarction may differ by age. We evaluated whether the efficacy and safety of de-escalation from ticagrelor to clopidogrel differed by age in stabilized patients after percutaneous coronary intervention (PCI). Patients and methods This was a prespecified secondary analysis of the TALOS-AMI randomized trial. Patients event-free 1 month after PCI receiving aspirin-ticagrelor were randomly allocated to de-escalation (aspirin-clopidogrel) or continuation (aspirin-ticagrelor). The primary net clinical endpoint was a composite of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) and Bleeding Academic Research Consortium types 2, 3, or 5 bleeding at 1 year. Results We included 2697 participants (mean age 60.0 ± 11.4 years; 16.8% women). Among patients aged <75 years (n = 2376), de-escalation reduced the primary net clinical endpoint (4.1% vs. 7.2%; adjusted hazard ratio (aHR), 0.54 [95% CI, 0.38-0.77]) and bleeding (2.8% vs. 4.9%; aHR, 0.54 [0.35-0.82]). Among patients aged ≥75 years, no significant differences were observed for the primary endpoint (6.4% vs. 11.6%; aHR0.54 [0.25-1.17]) or bleeding (3.2% vs. 7.9%; aHR, 0.41 [0.15-1.15]). Interaction testing showed no treatment effect modification by age for the primary endpoint (p for interaction = 0.978), MACE (p = 0.585), or BARC bleeding (p = 0.597). Among patients aged ≥75 years, 14/18 bleeding events occurred within 180 days. Conclusions Among stabilized, event-free patients 1 month after PCI, no significant age-treatment interaction was observed; therefore, the efficacy and safety of de-escalation in older adults (≥75 years) remain uncertain.Trial registration: ClinicalTrials.gov (NCT02018055).
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 10% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ████░ 4 | 20% | A qualitative jump: a capability or regime that did not exist before. |
| Evidence | █████ 5 | 32% | Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 5% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (relative gain, versus baseline, efficacy); novelty (open problem); design (randomized, registered); verification (confidence interval, error bars); stakes (mortality, major disease, prevention or cure).
How the score was computed
- Merit
- 7.2 / 10
- Adjusted merit
- 5.6 / 10
- Attention
- 0%
- Freshness
- 85%
- Citations0 (reference 20, via openalex, Oct 2, 2026, 06:17 UTC)
- Field-weighted citation impact0 (reference 3, via openalex, Oct 2, 2026, 06:17 UTC)